1. What is the projected Compound Annual Growth Rate (CAGR) of the U.S. Immunology Market?
The projected CAGR is approximately 10.3%.
U.S. Immunology MarketU.S. Immunology Market Unlocking Growth Opportunities: Analysis and Forecast 2025-2033
U.S. Immunology Market by Drug Class (Monoclonal Antibody (mAb), by Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Forecast 2025-2033
Base Year: 2024
100 Pages
U.S. Immunology Market Unlocking Growth Opportunities: Analysis and Forecast 2025-2033
U.S. Immunology Market Unlocking Growth Opportunities: Analysis and Forecast 2025-2033
Key Insights
The U.S. Immunology Market size was valued at USD 51.84 USD Billion in 2023 and is projected to reach USD 102.97 USD Billion by 2032, exhibiting a CAGR of 10.3 % during the forecast period. Immunology is the branch of biomedical science involved with looking at of the immune tool, its talents, troubles, and interactions with pathogens, tumors, and overseas substances. It includes numerous types, which consist of innate immunity, which offers immediate defense closer to infections, and adaptive immunity, which develops through the years and presents lengthy-lasting protection. Immunology features a complex network of cells, tissues, and molecules operating collectively to apprehend and get rid of pathogens at the same time as maintaining tolerance to self. Its applications span a giant variety, from developing vaccines and remedy options for infectious illnesses to treating autoimmune disorders and most cancers. In the United States, the present-day marketplace fashion in immunology reflects a developing demand for advanced diagnostic equipment, customized recuperation techniques, and immunomodulatory tablets, pushed through the increasing incidence of chronic illnesses and the emergence of new pathogens. This style is observed via significant investments in studies and development, fostering innovation in immunotherapy and precision remedy approaches.
U.S. Immunology Trends
- Rising incidence of autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
- Growing demand for biologics, particularly monoclonal antibodies, due to their high efficacy and specificity.
- Shifting landscape towards personalized medicine, with a focus on patient-specific treatments and therapies.
Driving Forces: What's Propelling the U.S. Immunology Market
- Rising prevalence of chronic diseases and autoimmune disorders.
- Introduction of innovative drugs and treatments.
- Technological advancements in drug development and delivery systems.
- Growing government and private sector funding for immunology research.
Challenges and Restraints in the U.S. Immunology Market
- High cost of immunology treatments.
- Side effects and safety concerns associated with certain immunology drugs.
- Regulatory hurdles and delays in approving new immunology therapies.
Emerging Trends in U.S. Immunology
- Precision medicine and personalized treatment approaches.
- Immuno-oncology and the development of cancer immunotherapies.
- Immunotherapy for infectious diseases, such as COVID-19.
Growth Catalysts in U.S. Immunology Industry
- Robust Government Support: Significant government funding and initiatives, spearheaded by agencies like the National Institutes of Health (NIH), particularly the National Institute of Allergy and Infectious Diseases (NIAID), and the Food and Drug Administration (FDA)'s Immunology Review Team, are driving innovation and accelerating the development of new immunotherapies. This includes grants, research contracts, and streamlined regulatory pathways.
- Strategic Public-Private Partnerships: Flourishing collaborations between leading pharmaceutical companies and renowned research institutions, exemplified by partnerships such as that between Merck and the Dana-Farber Cancer Institute, are fostering the development of cutting-edge immunotherapies and accelerating their translation from the laboratory to the clinic. These partnerships leverage the expertise and resources of both sectors.
- Technological Breakthroughs and Novel Therapies: Rapid advancements in biotechnology and immunology are yielding a pipeline of innovative therapies, including the transformative chimeric antigen receptor (CAR) T-cell therapies, increasingly sophisticated immune checkpoint inhibitors, and highly targeted monoclonal antibodies. These advancements are revolutionizing the treatment of various immunological diseases.
- Rising Prevalence of Immunological Disorders: The increasing incidence of autoimmune diseases, allergies, and infectious diseases fuels demand for effective immunotherapies, creating a strong market pull for innovation and growth.
- Increased Investment in R&D: Significant private sector investment in research and development is fueling the creation of new immunotherapeutic approaches and expanding the range of treatable conditions.
Leading Players in the U.S. Immunology Market
- AbbVie, Inc. (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Novartis AG (Switzerland)
- Merck Sharp & Dohme Corp. (U.S.)
- Pfizer Inc. (U.S.)
- Astellas Pharma Inc. (Japan)
- UCB SA (Belgium)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Amgen Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
Significant Developments in U.S. Immunology Sector
- August 2023: Regeneron Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for Veopoz (pozelimab-bbfg) to treat adult and pediatric patients one year of age and older with CHAPLE disease. This approval marks a significant milestone in the treatment of this rare and life-threatening disease.
- May 2023: Celltrion USA announced the U.S. FDA approval of Yuflyma (adalimumab-aaty), a high-concentration and citrate-free formulation of Humira (adalimumab) biosimilar. Yuflyma is indicated for the treatment of a range of inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis.
- May 2021: Bristol Myers Squibb Company announced that they received the U.S. FDA approval for Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD). Zeposia is a selective sphingosine 1-phosphate (S1P) receptor modulator that blocks the migration of certain immune cells into the gut, reducing inflammation and improving symptoms in UC patients.
Comprehensive Coverage U.S. Immunology Market Report
This report provides a comprehensive analysis of the U.S. Immunology market, including:
- Market Overview: A detailed analysis of the current market size, structure, and dynamics.
- Market Segmentation: A granular breakdown of the market by therapy type, disease indication, end-user, and geographic location.
- Market Trends: Identification of key trends shaping the future of the U.S. immunology market, including emerging therapies, technological advancements, and regulatory changes.
- Competitive Landscape: An in-depth analysis of the key players, their market share, competitive strategies, and R&D pipelines.
- Growth Drivers and Restraints: Identification of the factors driving market growth and the challenges that could hinder its progress.
- Forecasts and Projections: Detailed market forecasts and projections for the coming years, providing valuable insights for strategic decision-making.
- Pricing and Reimbursement Analysis: An examination of the pricing dynamics and reimbursement landscape, impacting market access and profitability.
Regional Insight
While the report focuses on the U.S. market, it may also include comparative analyses of other key regions, offering a broader global perspective. This may include:
- North America (Detailed U.S. data, with potential comparison to Canada and Mexico)
- Europe (Key European markets may be highlighted)
- Asia Pacific (Focus on key growth markets in the region)
- Latin America (Overview of the emerging market landscape)
DROCT
- Drivers: Rising prevalence of autoimmune diseases, technological advancements.
- Restraints: High cost of treatment, safety concerns.
- Opportunities: Growing demand for personalized medicine, emerging trends.
- Challenges: Regulatory hurdles, side effects.
- Threats: Competition from generics, patent expirations.
Pricing Analysis
The pricing analysis provides insights into the cost of immunology drugs and treatments, including:
- Factors Influencing Drug Pricing
- Comparison of prices across different drug classes
- Impact of insurance coverage and discounts
Import And Export Analysis
The import and export analysis examines the global trade of immunology products, including:
- Major exporting and importing countries
- Trade volume and value
- Impact of trade on market dynamics
Segmentation
Drug Class:
- Monoclonal Antibody (mAb)
- Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Interleukins
- Interferons
Disease Indication:
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Inflammatory Bowel Disease
- Prophylaxis of Organ Rejection
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Patent/Trademark Analysis
The patent/trademark analysis provides a comprehensive overview of intellectual property related to immunology drugs and treatments, including:
- Key patents and trademarks
- Patenting trends
- Impact of intellectual property on market dynamics
U.S. Immunology Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 10.3% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Surge in Cases of Autoimmune Disorders to Augment Market Growth
- 3.3. Market Restrains
- 3.3.1. Side Effects and High Cost Associated with Immunology Drugs Restrict Market Expansion
- 3.4. Market Trends
- 3.4.1. Growing Focus of Market Players on Research of New Types of Probes for Brain Implant
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. U.S. Immunology Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 5.1.1. Monoclonal Antibody (mAb
- 5.2. Market Analysis, Insights and Forecast - by Disease Indication
- 5.2.1. Rheumatoid Arthritis
- 5.2.2. Psoriatic Arthritis
- 5.2.3. Plaque Psoriasis
- 5.2.4. Ankylosing Spondylitis
- 5.2.5. Inflammatory Bowel Disease
- 5.2.6. Prophylaxis of Organ Rejection
- 5.2.7. Others
- 5.3. Market Analysis, Insights and Forecast - by Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Retail Pharmacies
- 5.3.3. Online Pharmacies
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1.
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 6. Northeast U.S. Immunology Market Analysis, Insights and Forecast, 2019-2031
- 7. Southeast U.S. Immunology Market Analysis, Insights and Forecast, 2019-2031
- 8. Midwest U.S. Immunology Market Analysis, Insights and Forecast, 2019-2031
- 9. Southwest U.S. Immunology Market Analysis, Insights and Forecast, 2019-2031
- 10. West U.S. Immunology Market Analysis, Insights and Forecast, 2019-2031
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2024
- 11.2. Company Profiles
- 11.2.1 AbbVie Inc. (U.S.)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Johnson & Johnson Services Inc. (U.S.)
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Eli Lilly and Company (U.S.)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Novartis AG (Switzerland)
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Merck Sharp & Dohme Corp. (U.S.)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Pfizer Inc. (U.S.)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Astellas Pharma Inc. (Japan)
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 UCB SA (Belgium)
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 F. Hoffmann-La Roche Ltd. (Switzerland)
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 Amgen Inc. (U.S.)
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 Bristol-Myers Squibb Company (U.S.)
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.1 AbbVie Inc. (U.S.)
List of Figures
- Figure 1: U.S. Immunology Market Revenue Breakdown (USD Billion, %) by Product 2024 & 2032
- Figure 2: U.S. Immunology Market Share (%) by Company 2024
List of Tables
- Table 1: U.S. Immunology Market Revenue USD Billion Forecast, by Region 2019 & 2032
- Table 2: U.S. Immunology Market Revenue USD Billion Forecast, by Drug Class 2019 & 2032
- Table 3: U.S. Immunology Market Revenue USD Billion Forecast, by Disease Indication 2019 & 2032
- Table 4: U.S. Immunology Market Revenue USD Billion Forecast, by Distribution Channel 2019 & 2032
- Table 5: U.S. Immunology Market Revenue USD Billion Forecast, by Region 2019 & 2032
- Table 6: U.S. Immunology Market Revenue USD Billion Forecast, by Country 2019 & 2032
- Table 7: Northeast U.S. Immunology Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 8: Southeast U.S. Immunology Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 9: Midwest U.S. Immunology Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 10: Southwest U.S. Immunology Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 11: West U.S. Immunology Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 12: U.S. Immunology Market Revenue USD Billion Forecast, by Drug Class 2019 & 2032
- Table 13: U.S. Immunology Market Revenue USD Billion Forecast, by Disease Indication 2019 & 2032
- Table 14: U.S. Immunology Market Revenue USD Billion Forecast, by Distribution Channel 2019 & 2032
- Table 15: U.S. Immunology Market Revenue USD Billion Forecast, by Country 2019 & 2032
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
Frequently Asked Questions
2. Which companies are prominent players in the U.S. Immunology Market?
Key companies in the market include AbbVie, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Eli Lilly and Company (U.S.), Novartis AG (Switzerland), Merck Sharp & Dohme Corp. (U.S.), Pfizer Inc. (U.S.), Astellas Pharma Inc. (Japan), UCB SA (Belgium), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen Inc. (U.S.), Bristol-Myers Squibb Company (U.S.).
3. What are the main segments of the U.S. Immunology Market?
The market segments include Drug Class, Disease Indication, Distribution Channel.
4. Can you provide details about the market size?
The market size is estimated to be USD 51.84 USD Billion as of 2022.
5. What are some drivers contributing to market growth?
Surge in Cases of Autoimmune Disorders to Augment Market Growth.
6. What are the notable trends driving market growth?
Growing Focus of Market Players on Research of New Types of Probes for Brain Implant.
7. Are there any restraints impacting market growth?
Side Effects and High Cost Associated with Immunology Drugs Restrict Market Expansion.
8. Can you provide examples of recent developments in the market?
August 2023: Regeneron Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for Veopoz (pozelimab-bbfg) to treat adult and pediatric patients one year of age and older with CHAPLE disease.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 2850, USD 3850, and USD 4850 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in USD Billion.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "U.S. Immunology Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the U.S. Immunology Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the U.S. Immunology Market?
To stay informed about further developments, trends, and reports in the U.S. Immunology Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.